Nash

Poxel Announces Participation at ODDO BHF Forum

Retrieved on: 
Thursday, December 19, 2019
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Steatohepatitis, RTT, Non-alcoholic fatty liver disease, ODDO BHF, Hepatitis, Nash, Seladelpar

POXEL SA (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will participate at the ODDO BHF Forum, which is being held on January 9-10, 2020, in Lyon, France.

Key Points: 
  • POXEL SA (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will participate at the ODDO BHF Forum, which is being held on January 9-10, 2020, in Lyon, France.
  • Members from the Poxel management team will be available to participate in one-on-one meetings with investors.
  • Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH).
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

Retrieved on: 
Thursday, December 5, 2019
Oncology, Health, Diabetes, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Branches of biology, Medicine, Hepatitis, RTT, Transcription factors, Steatohepatitis, Non-alcoholic fatty liver disease, NF-κB, Inflammation, Alcoholic liver disease, Nash

A large number of these meetings are with companies interested in Namodenoson in the treatment of NASH (non-alcoholic steatohepatitis) as well as Piclidenoson for anti-inflammatory indications.

Key Points: 
  • A large number of these meetings are with companies interested in Namodenoson in the treatment of NASH (non-alcoholic steatohepatitis) as well as Piclidenoson for anti-inflammatory indications.
  • Namodenoson has already been out-licensed for NASH in China and South Korea.
  • Namodenosons mechanism of action in NASH was highlighted in a recently published study in the International Journal of Molecular Medicine.
  • In pre-clinical studies, Namodenoson significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway.

Enzychem Lifesciences Presents EC-18 NASH Development Update at The Liver Meeting 2019

Retrieved on: 
Thursday, November 21, 2019
Medical specialties, Medicine, RTT, Non-alcoholic fatty liver disease, Steatohepatitis, Hepatitis, Liver disease, Cirrhosis, Nash, Fibrosis, Alcoholic liver disease, American Association for the Study of Liver Diseases

ENGLEWOOD CLIFFS, N.J., Nov. 21, 2019 /PRNewswire/ -- Enzychem Lifesciences Corporation (KOSDAQ: 183490), highlighted promising nonclinical data from its NASH candidate EC-18 at The Liver Meeting2019, hosted annually by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., Nov. 21, 2019 /PRNewswire/ -- Enzychem Lifesciences Corporation (KOSDAQ: 183490), highlighted promising nonclinical data from its NASH candidate EC-18 at The Liver Meeting2019, hosted annually by the American Association for the Study of Liver Diseases (AASLD).
  • Enzychem's poster presentation, titled: "EC-18, A Novel Immune Resolution Accelerator, Improves NASH (Nonalcoholic Steatohepatitis) and Liver Fibrosis," highlighted key nonclinical data for the company's lead NASH candidate EC-18, a novel immune resolution accelerator.
  • There are currently no FDA approved therapies for NASH, which causes liver inflammation and fibrosis.
  • Since its foundation in 1999, Enzychem Lifesciences has been striving to develop new and innovative treatments for patients with unmet medical needs.

Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019

Retrieved on: 
Tuesday, November 12, 2019
Research, FDA, Diabetes, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Medical specialties, Medicine, RTT, Non-alcoholic fatty liver disease, CYP17A1 inhibitors, Pyridines, Thiazolidinediones, Steatohepatitis, Thiazolidinedione, Pioglitazone, Hepatitis, Nash

POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).
  • In the poster presentation, PXL065 was observed to have a favorable safety, tolerability and PK profile in the Phase 1a trial.
  • Based on preclinical and clinical results, I am excited about the potential for an improved therapeutic profile for PXL065 compared to pioglitazone.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.

Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management

Retrieved on: 
Friday, November 8, 2019
Health, Other Health, Research, Pharmaceutical, Science, Biotechnology, Medicine, Clinical medicine, Branches of biology, Biomarker, Cell biology, Invasive procedure, Minimally invasive procedure, Non-invasive procedure, Nash

These preclinical results support the advancement of our proprietary synthetic biomarkers as we prepare to move into NASH clinical trials, said Caroline J Loew, PhD, President and CEO, Glympse Bio.

Key Points: 
  • These preclinical results support the advancement of our proprietary synthetic biomarkers as we prepare to move into NASH clinical trials, said Caroline J Loew, PhD, President and CEO, Glympse Bio.
  • NASH patient management is limited today by reliance on invasive procedures, and with the growth of the NASH population, a non-invasive alternative could provide significant benefit.
  • We look forward to continuing to develop our innovative technology to transform patient health with earlier measures of disease and treatment.
  • Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body.

Poxel to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 7, 2019
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Other Health, Medical specialties, Medicine, Hepatitis, Steatohepatitis, Non-alcoholic fatty liver disease, Nash, Euronext, Metabolic disorder, Seladelpar

POXEL S.A. (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November:

Key Points: 
  • POXEL S.A. (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November:
    The Jefferies 2019 London Healthcare Conference presentation will be live streamed via webcast.
  • Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH).
  • Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Echosens FAST Score Revolutionizes the Assessment of NASH: Cost-Effective, Efficient Identification of Individuals at Risk for Active Fibrotic NASH

Retrieved on: 
Thursday, November 7, 2019
Biotechnology, Diabetes, AIDS, Health, Other Health, Pharmaceutical, Oncology, Practice Management, Medical devices, Managed care, Infectious diseases, Hospitals, Clinical trials, Cardiology, Liver, Organs, Nash, Hepatology, Hepatitis, Echosens, the University of Birmingham, The National Institute for Health Research (NIHR)

FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.

Key Points: 
  • FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
  • FAST score provides an efficient way to non-invasively identify at-risk patients with progressive NASH that merit consideration for further treatment.
  • This is very timely and significant because the efficient identification of active fibrotic NASH has long been a challenge for drug companies, and many are now developing drugs targeting this disease.
  • FAST is simple to determine and interpret just requiring three numbers entered into a calculator, he adds, further explaining that FAST score provides a probability of active fibrotic-NASH.

Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

Retrieved on: 
Wednesday, November 6, 2019
Medical specialties, Medicine, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Nash, Hepatitis, Madrigal

CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:

Key Points: 
  • CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:
    Madrigal continued to execute its clinical development strategy in non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) during the third quarter.
  • Becky Taub, M.D.,CMO, President, Research & Development of Madrigal, added, We are pleased to announce that The Lancet has accepted for publication Madrigals Phase 2 study results in patients with NASH.
  • We are also pleased to announce that FDA has granted Madrigals request for Fast Track designation of resmetirom for NASH.
  • Financial Results for the Three and Nine Months EndedSeptember 30, 2019
    As of September 30, 2019, Madrigal had cash, cash equivalents and marketable securities of $453.6 million, compared to $483.7 million at December 31, 2018.

InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform

Retrieved on: 
Monday, November 4, 2019
Medical specialties, Medicine, Hepatitis, Health sciences, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Liver disease, Liver, Pre-clinical development, Nash, Drug discovery

At the event, InSphero highlighted its 3D InSight Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a breakthrough 3D cell technology for drug discovery and safety testing.

Key Points: 
  • At the event, InSphero highlighted its 3D InSight Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), a breakthrough 3D cell technology for drug discovery and safety testing.
  • InSphero platformswill benefit Chinese researchers in academia and industry working at the forefront of complex disease drug discovery.
  • This game-changing preclinical discovery platform enables scalable in vitro drug efficacy assessment, screening, combinatorial testing as well as the study of complex NASH pathophysiology.
  • For more information about the 3D InSight Human Liver Disease Platform for NAFLD and NASH and InSphero's portfolio of InSight platforms for metabolic disease discovery, oncology, and toxicology, visit www.insphero.com .

PharmaNest Announces New Adult and Pediatric NASH Data to Be Presented at the AASLD - Liver Meeting® 2019

Retrieved on: 
Wednesday, October 30, 2019
Medical specialties, Medicine, Hepatitis, Histopathology, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Steatosis, Liver disease, Nash, Alcoholic liver disease, Liver

PRINCETON, N.J., Oct. 30, 2019 /PRNewswire/ --PharmaNest is an image analysis company focused on the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

Key Points: 
  • PRINCETON, N.J., Oct. 30, 2019 /PRNewswire/ --PharmaNest is an image analysis company focused on the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.
  • Recently, PharmaNest announced the launch of its FibroNest cloud-based and multi-vendor platform for the automated quantification of Fibrosis for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), for research-only-use projects at this time.
  • The Platform has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions, including more than 40 traits and +350 parameters.
  • Results in Adult NASH and Pediatric NASH will be presented at the Liver Meeting, including the following poster presentations:
    Fine Collage (green) - Assembled Collagen (red) - Steatosis (gray with white, dotted lines circumference)
    View original content to download multimedia: http://www.prnewswire.com/news-releases/pharmanest-announces-new-adult-a...